<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Members of the <z:mp ids='MP_0011356'>RAS</z:mp> gene family have been implicated in many <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with activating mutations around amino acid positions 12 and 61 </plain></SENT>
<SENT sid="1" pm="."><plain>We have assessed the mutational activation of H, K, and NRAS in <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) by polymerase chain reaction and hybridization with synthetic oligonucleotide probes </plain></SENT>
<SENT sid="2" pm="."><plain>Using this method, point mutations in codons 12/13 and 61 of these <z:mp ids='MP_0011356'>RAS</z:mp> genes were detected in 20 of 50 patients including two with <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Ten <z:mpath ids='MPATH_458'>normal</z:mpath> individuals had no detectable <z:mp ids='MP_0011356'>RAS</z:mp> mutations </plain></SENT>
<SENT sid="4" pm="."><plain>In 11 instances, DNA from patients with detectable <z:mp ids='MP_0011356'>RAS</z:mp> mutations were shown to register in either NIH3T3 focus-forming or <z:mp ids='MP_0003815'>nude</z:mp> mouse tumorigenicity assays </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, one patient (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) was shown to have an activated NRAS gene detected by a tumorigenicity assay and Southern blot analyses </plain></SENT>
<SENT sid="6" pm="."><plain>Two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients had mutations detected in two different <z:mp ids='MP_0011356'>RAS</z:mp> genes </plain></SENT>
<SENT sid="7" pm="."><plain>DNA from one of these patients was observed to give rise to transformants with activated N and HRAS </plain></SENT>
<SENT sid="8" pm="."><plain>Two patients with detectable NRAS mutations in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> stage progressed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and DNA from the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> stage registered positively in a transformation assay with NRAS activation </plain></SENT>
<SENT sid="9" pm="."><plain>These results show that <z:mp ids='MP_0011356'>RAS</z:mp> mutations can occur at early, as well as late, stages of leukemic progression </plain></SENT>
<SENT sid="10" pm="."><plain>The incidence of <z:mp ids='MP_0011356'>RAS</z:mp> mutations appears to be significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> than in the other subgroups (p = 0.02) </plain></SENT>
</text></document>